Healthcare Bullish Stocks: Agios Pharmaceuticals (NASDAQ:AGIO), Rockwell Medical (NASDAQ:RMTI), OHR Pharmaceutical (NASDAQ:OHRP), Emergent Biosolutions (NYSE:EBS)

Agios Pharmaceuticals Inc (NASDAQ:AGIO) SVP Glenn Goddard sold 17,468 shares of the stock on the open market in a transaction that occurred on Friday, March 7th. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was 13.82 % in last session and finished the day at $ 45.45. Traded volume was 1,334,731 million shares in the last session and the average volume of the stock remained 283.01 million shares. Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider ownership is 0.40%.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was a big mover last session, as the company saw its shares rise by over 26% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. some stocks in the same industry looking equally good include Enzymotec Ltd. ( ENZY ), Rockwell Medical, Inc. (NASDAQ:RMTI) and William Demant Holding A/S ( WILYY ). Rockwell Medical Inc (NASDAQ:RMTI) rose 5.38 percent to $14.11 Friday on volume of 1.24million shares. The intra-day range of the stock was $13.20 to $14.15. Rockwell Medical Inc (NASDAQ:RMTI) has a market capitalization of $564.37million.

Cytosorbents Corporation (OTCBB:CTSO) share price has doubled, Mast Therapeutics, Inc. (NYSE MKT: MSTX) and OHR Pharmaceutical, Inc. (NASDAQ:OHRP) are both up approximately 85% and Accelerize New Media, Inc. (OTCBB:ACLZ) is up 20%.” OHR Pharmaceutical Inc (NASDAQ:OHRP)’s stock on Mar 7, 2014 reported a increase of 22.02% to the closing price of $17.73. Its fifty two weeks range is $4.11-$17.85. The total market capitalization recorded $354.07million. The overall volume in the last trading session was 1.16million shares. In its share capital, OHRP has 19.87million outstanding shares.

Biodel Inc. (NYSE:EBS), a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes, has signed a long-term manufacturing agreement with Cangene bioPharma Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc (NYSE:EBS) for development of its Glucagon Emergency Management (GEM) programme. On Friday, shares of Emergent Biosolutions Inc (NYSE:EBS) advanced 8.60% to close the day at $27.77. Company return on investment (ROI) is 3.20% and its monthly performance is recorded as 17.87%. Emergent Biosolutions Inc (NYSE:EBS) quarterly revenue growth is 23.20%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone